Research shows approach that includes sequencing both normal genomes and tumor genomes increases accuracy and precision
NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, and NantOmics, LLC, the leader in molecular diagnostics and a member of the NantWorks ecosystem of families, announced today joint results that show significant improvements in the accuracy of diagnosis when combining tumor-normal DNA analysis with tumor RNA analysis — as well as the risk for a higher error rate in tumor only sequencing. ... |